Novo Nordisk Pharma AG
http://www.novonordisk.ch
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Novo Nordisk Pharma AG
Obesity Drugs Cost Concerns Not Yet Impacting HHS Risk Adjustment Models
Individual and small group plans in the commercial insurance market are not seeing ‘a large enough change in clinical indications or practice patterns to warrant a change to the current mapping of GLP-1 drugs,’ final rule states.
Drug Cost-Sharing Limits Could Be Strengthened In Self-Insured, Large Group Plans In Upcoming Rule
Proposal would extend the reach of CMS policy for drugs covered by individual and small group plans and could be an important step toward reining in copay maximizers and alternative funding programs in the commercial market.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
US Medicare Plans 'Can' Cover Wegovy, CMS Says, But Will They?
Medicare is making clear that Part D ‘can’ cover GLP-1 inhibitors that are approved for cardiovascular indications – but in language that seems to leave plans considerable discretion for now. The formulary review process for 2025 may be a more important milestone for changes.
Company Information
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice